20.500.12556/DiRROS-22880 Boj proti bakterijski odpornosti ali so bakterijske topoizomeraze tipa II še zanimive tarče? The fight against bacterial resistance are bacterial type II topoisomerases still interesting targets? Topoizomeraze tipa II so pomembne tarče za proti - bakterijsko terapijo. Prvi zaviralci topoizomeraz tipa II, kinoloni in aminokumarini, so se na trgu pojavili že pred desetletji, vendar njihova uporabnost postopoma upada zaradi nizke učinkovitosti, neželenih učinkov in pojava bakterijske rezistence. Za premagovanje odpornosti in ohranjanje topoizomeraz kot zanimivih tarč, so ključne inovacije na tem področju – izboljšanje dosedanjih razredov učinkovin in odkrivanje novih tipov zaviralcev. V članku so predstavljeni različni razredi zaviralcev bakterijskih topoizomeraz, njihove prednosti in slabosti ter obeti za prihodnost. Type II topoisomerases are important targets for antibacterial therapy. The first inhibitors of type II topoisomerases, quinolones and aminocoumarins, emerged more than half a century ago, but their use is now in slow decline due to toxic side effects, low effectiveness and emergence of bacterial resistance. Innovations in this field – improvement of already existing classes of antibacterials and discovery of novel classes of compounds, are essential for overcoming resistance and maintaining topoisomerases as viable targets. In this paper, we present various classes of bacterial topoisomerase inhibitors, their advantages and shortcomings, as well as future perspectives. aminokumarini novi zaviralci bakterijskih topoizomeraz kinoloni protibakterijska terapija zaviralci topoizomeraze tipa II true false true Slovenski jezik Angleški jezik Neznano 2025-07-07 14:30:59 2025-07-08 07:43:24 2025-10-24 03:52:25 0000-00-00 00:00:00 2025 0 0 str. 10-21 Št. 1 Letn. 76 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2025-01-01 615.015.8 0014-8229 230959875 RAZ_Zorman_Masa_2025.pdf RAZ_Zorman_Masa_2025.pdf 1 713BC6AB67727047AFFD9EE666DA450B 61d7bb59fa1d8d4174495e60c9d121fb39801e28c9d6f124286724f71dd2a20d 626661be-5bbe-11f0-8080-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=33317 Slovensko farmacevtsko društvo Farmacevtski vestnik 0 0 0